Outlook Therapeutics, Inc.

OTLK

Outlook Therapeutics, Inc.

OTLK

Insider Sentiment (TTM):

Last Purchase:2026-06-02Last Sale:-Shares Purchased (TTM):9,129,883Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:10,545,006Shares Outstanding:81,835,900Institutional Ownership Pct.:12.89%

Earnings Market Reaction:

Filing Date:2026-08-18Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	11	8	9	8	9	8	6	15	32	47	10	23
Accounts Receivable Net Current	2	3	0	1	2	-	-	-	-	-	-	-
Inventory Net	5	3	3	3	4	4	3	-	-	-	-	-
Prepaid Expense And Other Assets Current	5	7	5	4	6	7	7	12	14	11	10	8
Assets Current	23	21	17	17	21	18	16	27	46	58	20	31
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Equity Method Investments	3	0	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	1
Assets	26	22	18	19	22	19	17	29	47	59	22	32
Liabilities And Stockhold…
Liabilities Current
Notes And Loans Payable Current	-	10	37	30	14	12	31	29	32	45	37	36
Finance Lease Liability Current	-	-	-	-	-	-	-	-	-	-	0	0
Unsecured Debt Current	18	6	-	-	-	-	-	-	-	-	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	-	-	-
Accounts Payable Current	7	14	7	10	10	8	12	8	6	4	3	7
Accrued Liabilities Current	3	9	5	5	5	3	3	3	3	3	4	3
Accrued Income Taxes Current	0	0	0	0	2	2	2	2	2	2	2	2
Liabilities Current	29	39	49	46	31	25	48	43	43	54	46	47
Long Term Notes And Loans	-	11	-	-	20	21	-	-	-	-	-	-
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	-	-	-
Warrants And Rights Outstanding	8	1	8	5	7	5	19	59	88	139	0	0
Liabilities	37	51	57	51	60	52	67	102	131	193	46	47
Stockholders Equity
Temporary Equity
Common Stock Value	2	1	1	1	0	0	0	0	0	0	3	0
Additional Paid In Capital Common Stock	641	603	590	573	555	539	475	470	465	459	452	453
Retained Earnings Accumulated Deficit	-654	-633	-629	-606	-592	-572	-526	-543	-549	-593	-479	-468
Stockholders Equity	-10	-29	-39	-32	-37	-32	-50	-73	-84	-134	-24	-14
Liabilities And Stockholders Equity	26	22	18	19	22	19	17	29	47	59	22	32
Series A Preferred Stock	-	-	-	-	-	-	-	-	-	0	0	0
Series A1 Convertible Preferred Stock	-	-	-	-	-	-	-	-	-	0	0	0
Series B Preferred Stock	-	-	-	-	-	-	-	-	-	0	0	0
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	7	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	260	260	260	260	260	60	60	260	60	21	425	60
Common Stock Shares Issued	187	105	65	54	43	33	25	24	23	22	13	13
Shares Outstanding	187	105	65	54	43	33	25	24	23	22	13	13

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.64%	-41.00%	-47.63%	240.79%	535.96%	328.51%	-	-	-	-	-	-
2025	-20.32%	-35.83%	-17.11%	13.43%	6.27%	15.22%	-61.52%	-56.38%	-48.15%	-70.65%	-78.66%	-79.40%
2024	-5.95%	10.24%	2.38%	-8.61%	-1.48%	-1.35%	8.31%	-28.75%	-17.57%	10.95%	-6.97%	-21.89%
2023	-	-	-	-	-	-	-	-	-	-13.00%	-2.13%	-6.62%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.81	0.54	0.35	0.38	0.67	0.72	0.32	0.64	1.07	1.07	0.44	0.66
Quick Ratio	0.45	0.27	0.18	0.21	0.34	0.30	0.12	0.35	0.75	0.87	0.23	0.50
Working Capital	-5.51M	-17.98M	-31.89M	-28.43M	-10.39M	-7.02M	-32.57M	-15.14M	3.06M	3.71M	-25.58M	-15.75M
Leverage & Debt
Debt to Equity	-3.52	-1.76	-1.47	-1.58	-1.60	-1.59	-1.34	-1.39	-1.56	-1.44	-1.89	-3.24
Interest Coverage TTM	-210.61	-193.21	-177.52	-176.07	-92.76	-19.65	-11.93	-10.10	-9.10	-16.73	-69.97	-18.05
Debt Ratio	1.40	2.32	3.11	2.73	2.66	2.70	3.96	3.54	2.78	3.27	2.12	1.45
Efficiency & Turnover
Asset Turnover TTM	-0.00	0.07	0.08	0.06	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	-6,751.69	702.31	29.59	384.99	424.67	-	-	-	-	-	-	-
Receivables Turnover TTM	-0.05	0.52	12.33	0.95	0.86	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-0.45	-0.74	-1.71	-1.79	-1.18	0.68	-1.93	-4.06	-3.69	-11.15	-3.96	-4.72
Free Cash Flow Per Share TTM	-0.41	-0.57	-0.93	-1.49	-1.53	-2.07	-2.75	-3.71	-2.78	-4.08	-3.62	-3.44
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	2,479.56%	-85.05%	-	-	-	-	-	-	-	-	-	-
Operating Profit Margin TTM	60,613.98%	-4,285.30%	-4,169.60%	-4,744.25%	-4,824.52%	-	-	-	-	-	-	-
Net Profit Margin TTM	66,592.50%	-4,312.34%	-7,276.84%	-4,416.22%	-2,885.82%	-	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-106.10%	-	-	-	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	40.70%	-388.61%	119.74%	-17.17%	-53.81%	-113.27%	-9.10%	27.78%	55.87%	178.20%	-26.69%	-10.70%
EPS Growth (1Y)	-61.97%	-208.88%	-11.55%	-55.85%	-70.97%	-106.13%	-51.19%	-13.83%	-13.81%	150.18%	-35.95%	-24.30%
Valuation Metrics
P/E TTM	-3.56	-0.28	-0.92	-0.59	-1.36	1.78	-0.98	-1.31	-1.82	-1.07	-1.99	-0.94
P/B TTM	-20.92	-0.58	-2.47	-1.15	-1.59	-1.16	-0.91	-1.36	-2.05	-1.27	-4.21	-3.83
P/S TTM	-2,368.77	11.93	67.30	26.09	39.28	-	-	-	-	-	-	-
Market Cap	217.42M	16.86M	95.12M	36.88M	59.13M	37.67M	45.80M	99.05M	171.42M	170.39M	102.54M	55.29M
Enterprise Value	224.41M	15.11M	86.45M	28.80M	50.23M	30.11M	40.10M	84.12M	139.39M	123.16M	92.19M	31.90M
Calculated Values
Free Cash Flow TTM	-56.15M	-47.05M	-55.80M	-51.83M	-56.43M	-64.05M	-66.73M	-68.79M	-64.55M	-58.26M	-47.10M	-42.97M
Net Debt	6.98M	-1.75M	-8.68M	-8.08M	-8.90M	-7.56M	-5.70M	-14.93M	-32.02M	-47.23M	-10.36M	-23.39M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-02Purchase

Owner: Haddadin, Yezan Munther

Title: -

Shares: 29,000

Price/Share: $0.83

Value: $24,070.00

Shares Owned: 66,167

Relationship: Director

Ownership: Direct

2026-05-28Purchase

Owner: Gms, Ventures & Investmen…

Title: -

Shares: 8,539,709

Price/Share: $0.59

Value: $5,038,428.31

Shares Owned: 22,092,068

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-05-27Purchase

Owner: Sukhtian, Faisal Ghiath

Title: -

Shares: 122,174

Price/Share: $0.41

Value: $50,091.34

Shares Owned: 125,574

Relationship: Director

Ownership: Direct

2026-05-26Purchase

Owner: Haddadin, Yezan Munther

Title: -

Shares: 34,000

Price/Share: $0.44

Value: $14,960.00

Shares Owned: 37,167

Relationship: Director

Ownership: Direct

2026-05-26Purchase

Owner: Thurman, Randy H

Title: -

Shares: 5,000

Price/Share: $0.43

Value: $2,150.00

Shares Owned: 5,593

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-02	Haddadin, Yezan Munther	Director	-	Direct	Purchase	29,000	0.83	$24,070.00	66,167	4
2026-05-28	Gms, Ventures & Investmen…	Director,TenPercentOwner	-	Indirect	Purchase	8,539,709	0.59	$5,038,428.31	22,092,068	4
2026-05-27	Sukhtian, Faisal Ghiath	Director	-	Direct	Purchase	122,174	0.41	$50,091.34	125,574	4
2026-05-26	Haddadin, Yezan Munther	Director	-	Direct	Purchase	34,000	0.44	$14,960.00	37,167	4
2026-05-26	Thurman, Randy H	Director	-	Direct	Purchase	5,000	0.43	$2,150.00	5,593	4
2026-05-26	Hilzinger, Kurt J	Director	-	Direct	Purchase	400,000	0.44	$176,000.00	423,655	4
2024-09-26	Kenyon, Lawrence A	Director,Officer	Chief Financial Officer	Direct	Purchase	5,000	5.69	$28,450.00	5,946	4
2024-04-15	Syntone, Ventures Llc	TenPercentOwner	-	Direct	Purchase	714,286	-	-	1,705,438	4
2024-03-28	Haddadin, Yezan Munther	Director	-	Direct	Purchase	1,882	11.82	$22,241.81	5,049	4
2024-03-07	Evanson, Jeff	Officer	CHIEF COMMERCIAL OFFICER	Direct	Purchase	62,484	0.42	$26,243.28	808,459	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

12.89%

Inst. Shares: 10,545,006

Shares Outstanding: 81,835,900

2025-12-31

11.44%

Inst. Shares: 6,887,051

Shares Outstanding: 60,205,035

2025-09-30

11.04%

Inst. Shares: 3,841,514

Shares Outstanding: 34,796,120

2025-06-30

15.86%

Inst. Shares: 5,862,714

Shares Outstanding: 36,956,582

2025-03-31

22.77%

Inst. Shares: 7,030,535

Shares Outstanding: 30,874,396

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	10,545,006	81,835,900	12.89%
2025-12-31	6,887,051	60,205,035	11.44%
2025-09-30	3,841,514	34,796,120	11.04%
2025-06-30	5,862,714	36,956,582	15.86%
2025-03-31	7,030,535	30,874,396	22.77%
2024-12-31	4,393,273	24,233,957	18.13%
2024-09-30	7,893,497	18,548,813	42.56%
2024-06-30	8,037,155	23,227,069	34.60%
2024-03-31	7,164,528	14,270,289	50.21%
2023-12-31	28,905,201	13,012,833	222.13%
2023-09-30	26,843,944	12,508,817	214.60%
2023-06-30	28,973,520	12,844,079	225.58%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Outlook Therapeutics, Inc. (OTLK) — SEC Financial Statements & Analysis

Outlook Therapeutics, Inc. (OTLK) is a biological products, (no diagnostic substances) company, incorporated in DE. Outlook Therapeutics, Inc. trades on Nasdaq as: OTLK. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Outlook Therapeutics, Inc. reported a -106.10% year-over-year revenue growth, a Gross Profit Margin of 2479.56% (TTM), a Debt-to-Equity ratio of -3.52x, a Price-to-Sales (P/S) ratio of -2368.77x (TTM), a Price-to-Book (P/B) ratio of -20.92x (TTM), at a market cap of $217.42M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -106.10%
Gross Profit Margin TTM: 2479.56%
Debt To Equity: -3.52x
P/S TTM: -2368.77x
P/B TTM: -20.92x
Market Cap: $217.42M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Outlook Therapeutics, Inc. in?

Outlook Therapeutics, Inc. (OTLK) operates in the Biological Products, (No Diagnostic Substances) industry.

What is OTLK's market cap?

Outlook Therapeutics, Inc. (OTLK) has a market capitalization of $217.42M as of 2026-06-30.

What exchange does OTLK trade on?

Outlook Therapeutics, Inc. (OTLK) trades on the Nasdaq.

Where is Outlook Therapeutics, Inc. incorporated?

Outlook Therapeutics, Inc. is incorporated in DE.